RCT: Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease.
30 May, 2022 | 11:14h | UTCRisankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial – The Lancet (link to abstract – $ for full-text)